Today: 21 May 2026
Trump vs. Jamie Dimon Over Fed Independence Escalates as IMF and Fitch Warn of Higher Rates
15 January 2026
2 mins read

Trump vs. Jamie Dimon Over Fed Independence Escalates as IMF and Fitch Warn of Higher Rates

WASHINGTON, Jan 15, 2026, 17:10 EST

  • IMF chief Kristalina Georgieva threw her support behind Fed Chair Jerome Powell as he faces mounting political pressure on the central bank
  • Trump said he doesn’t plan to fire Powell, but Dimon cautioned that meddling could eventually push rates higher
  • Fitch warned that a significant loss of Fed independence would harm the U.S. credit rating

International Monetary Fund Managing Director Kristalina Georgieva threw her support behind Federal Reserve Chair Jerome Powell on Thursday, emphasizing that central bank independence remains crucial as the Trump administration applies pressure amid a Justice Department probe into renovation cost overruns. “He is a very good professional, very decent man,” Georgieva said, describing the Fed as “precious” because of the dollar’s key global role. Reuters

Why it matters now: the Fed controls the benchmark interest rate, which shapes borrowing costs economy-wide—from mortgages and credit cards to corporate loans. It’s meant to operate independently, free from daily political influence.

Bankers and policymakers warn that interfering with this process could backfire. Should investors start doubting the central bank’s commitment to its mandate, inflation expectations—what households and markets anticipate prices will do next—could rise, along with the interest rates investors demand in bond markets.

Trump told Reuters on Wednesday he has no plans to fire Powell despite the ongoing investigation but said it’s “too early” to say what he might do in the end. He mentioned former Fed Governor Kevin Warsh and National Economic Council Director Kevin Hassett as possible replacements, while ruling out Treasury Secretary Scott Bessent. Powell’s term as chair ends in May, though he could stay on the Fed’s Washington board until 2028. Reuters

Trump fired back at Wall Street critics after JPMorgan Chase CEO Jamie Dimon cautioned that undermining Fed independence is “not a great idea.” Trump called Dimon “wrong” and insisted the U.S. “should have lower” rates. He also hinted Dimon might favor higher rates because “maybe he makes more money that way.” The Guardian

Fitch chimed in on the credit front. James Longsdon, who heads the firm’s sovereign ratings, warned that a “complete politicization of a central bank” would hit creditworthiness hard. He stressed that trust in the dollar as a reserve currency is crucial for the U.S. rating, though he noted there’s no evidence of that threat right now. Reuters

In Europe, ECB policymaker Martins Kazaks described the pressure on Powell as reminiscent of “emerging market politics” and cautioned against complacency, warning that such actions might drive inflation higher and push U.S. interest rates up later. Reuters

The dispute has spilled beyond borders. New Zealand’s foreign minister took aim at the central bank governor for endorsing Powell, telling her to “stay in her New Zealand lane” after she aligned with other central bankers in “full solidarity” with the Fed chair. Reuters

The endgame remains unclear. Efforts to oust Powell may face legal hurdles and political roadblocks, like the need for Senate approval of a replacement. Critics caution that dragging out this pressure risks shaking confidence and driving borrowing costs higher—exactly the opposite of what the White House aims for.

Powell has denied any wrongdoing, calling the investigation a pretext aimed at pressuring rate decisions. The Trump administration argues it must probe possible misconduct, sparking a dispute that stretches from Wall Street to foreign capitals.

Stock Market Today

  • Stock Market Futures Fall on May 20, 2026, as Investors React to Nvidia Earnings
    May 20, 2026, 7:32 PM EDT. U.S. stock futures dropped Wednesday evening, reflecting investor caution after Nvidia ($NVDA) reported earnings. The AI chipmaker's results sparked debate over whether they met lofty expectations, influencing market sentiment ahead of Thursday's open. Futures contracts, which allow investors to buy or sell assets at a predetermined price for future delivery, indicated a tentative market tone. Traders are assessing Nvidia's outlook amid broader concerns about the tech sector's growth momentum and valuation pressures. This cautious stance highlights the sensitive market environment as investors balance strong earnings reports against economic headwinds and sector-specific risks.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Netflix stock slips after hours as Sony film deal lands and Warner bid fight heats up
Previous Story

Netflix stock slips after hours as Sony film deal lands and Warner bid fight heats up

Dow Jones today: Index jumps nearly 300 points as Goldman earnings and TSMC outlook lift Wall Street
Next Story

Dow Jones today: Index jumps nearly 300 points as Goldman earnings and TSMC outlook lift Wall Street

Go toTop